Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM2O4MI)

• Drug Name: UK-432097 Drug Info
• Synonyms: Adenosine A2a agonist (asthma), Pfizer

Indication

Disease Entry	ICD 11	Status	REF
Chronic obstructive pulmonary disease	CA22	Phase 2	[1]

• Cross-matching ID:
  PubChem CID: 9833519
  CAS Number: CAS 380221-63-6
  TTD Drug ID: DM2O4MI

Molecule-Related Drug Atlas

Drug(s) Targeting Adenosine A2a receptor (ADORA2A)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Caffeine	DMKBJWP	Allergic rhinitis	CA08.0	Approved	[3]
Istradefylline	DM20VSK	Parkinson disease	8A00.0	Approved	[4]
Regadenoson	DM76VHG	Radionuclide imaging	N.A.	Approved	[5]
Tozadenant	DMATC14	Parkinson disease	8A00.0	Phase 3	[6]
Binodenoson	DMVHF8G	Hypertension	BA00-BA04	Phase 3	[7]
Apadenoson	DMD8QTC	Coronary artery disease	BA80	Phase 3	[8]
Tonapofylline	DMBH316	Acute and chronic heart failure	BD1Z	Phase 2	[9]
Dexefaroxan	DMTY4KN	Parkinson disease	8A00.0	Phase 2	[10]
AMP-579	DMJ4GPR	Hyperlipidaemia	5C80	Phase 2	[11]
BIIB014	DMH7RJ1	Parkinson disease	8A00.0	Phase 2	[12]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Adenosine A2a receptor (ADORA2A)	TTM2AOE	AA2AR_HUMAN	Agonist	[2]

References

• [1] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8420).
• [2] Structure of an agonist-bound human A2A adenosine receptor. Science. 2011 Apr 15;332(6027):322-7.
• [3] Caffeine as a psychomotor stimulant: mechanism of action. Cell Mol Life Sci. 2004 Apr;61(7-8):857-72.
• [4] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019
• [5] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
• [6] Tozadenant (SYN115) in patients with Parkinson's disease who have motor fluctuations on levodopa: a phase 2b, double-blind, randomised trial. Lancet Neurol. 2014 Aug;13(8):767-76.
• [7] Coronary circulation responses to binodenoson, a selective adenosine A2A receptor agonist. Am J Cardiol. 2007 Jun 1;99(11):1507-12.
• [8] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 3290).
• [9] 2-Amino-5-benzoyl-4-phenylthiazoles: Development of potent and selective adenosine A1 receptor antagonists. Bioorg Med Chem. 2010 Mar 15;18(6):2195-2203.
• [10] The pipeline and future of drug development in schizophrenia. Mol Psychiatry. 2007 Oct;12(10):904-22.
• [11] Adenosine A1/A2a receptor agonist AMP-579 induces acute and delayed preconditioning against in vivo myocardial stunning. Am J Physiol Heart Circ Physiol. 2004 Dec;287(6):H2746-53.
• [12] Novel pharmacological targets for the treatment of Parkinson's disease. Nat Rev Drug Discov. 2006 Oct;5(10):845-54.